Participated · Series C · Sep 2025

Founded in 2017, Inventchip is a Chinese integrated device manufacturer focused on silicon carbide (SiC) power semiconductors and related driver and control ICs. The company has mass-produced three generations of SiC MOSFETs that it says meet advanced industry performance standards. Its products are embedded in EV onboard chargers, DC-DC converters, e-drive systems, air-conditioning compressors, photovoltaics, energy storage units, charging piles and industrial power supplies. By 2024, Inventchip had shipped more than 16 million SiC MOSFETs, 18 million SiC Schottky barrier diodes and nearly 60 million driver ICs. The firm has also entered the EV main drive inverter market, securing projects with multiple automakers and suppliers. Proceeds from its latest financing will be used to expand SiC production capacity, accelerate product R&D and support broader market promotion.

Led · Series A · Jan 2024

洪启集成 (Hongqi Integrated Circuits) specializes in chip analysis and testing services across the full development and supply chain. Its offerings include reverse engineering, circuit repair, failure analysis, materials analysis, reliability testing, reliability system construction, and yield analysis and improvement. The company serves chip design houses, manufacturers, packaging providers, and suppliers of raw materials and equipment. Its work focuses on accelerating product and process R&D and improving product quality for clients. Following its recent financing, 洪启集成 will continue to deepen R&D in high-end chip detection and analysis technologies. The company aims to provide professional, precise, full-process, and high-timeliness high-end chip analysis and testing services.

Led · Series B · Jan 2024

Avistone Biotechnology is an oncology company focused on developing targeted therapies for patients with unmet medical needs, with a lead asset PLB1001 (Vebreltinib) that targets MET tyrosine kinase activity. PLB1001 recently received conditional approval from the NMPA for MET exon 14 skipping NSCLC in China. The company also develops PLB1004, an EGFR tyrosine kinase inhibitor including activity against EGFR exon20 insertion mutations. Avistone has built a commercial sales and marketing team covering 25 provinces, nearly 1,000 hospitals, and hundreds of commercial companies and retail outlets in China. The company plans to use recent financing to support clinical research and development, internal combination studies, accelerated screening of new molecules, and expansion of clinical studies and commercialization in the United States. Avistone positions itself to continue advancing its pipeline and commercialization efforts while expanding global clinical development.

Led · Series B · Jan 2024

Zhongyin Microelectronics is a hardcore interface IP technology supplier concentrating on high-end IP research and development, advanced-process IC design, and Chiplet architecture and development. The company targets high-performance computing and network communications customers, offering advanced-process interface IP, one-stop high-end SoC customization, and advanced Chiplet packaging products. Beyond IP, Zhongyin is developing self-owned Chiplet products to address agile development needs in the post‑Moore era. Recently the company completed a B round financing of over ¥100 million. Proceeds will be used to advance enterprise-grade high-speed interface IP and Chiplet product R&D, accelerate Chiplet product commercialization, and support talent recruitment. Existing investor Zhuoyuan Capital participated in follow-on investment while the round was led by Guotou Chuangye.

Led · Series C · Sep 2023

Canton Biologics is a molecule biopharmaceutical CDMO founded in Guangzhou in 2016 by Dr. Xiao Shen. The company provides end-to-end services from biopharmaceutical CMC development to commercial production and global clinical supply. It has capabilities in high-yield cell line development, complex protein expression, and international manufacturing. Canton has made advancements in its IgM molecule expression platform, expression host cells, high-density cell culture, new formulations, and analytical methodologies. The company raised over 300M Yuan in a Series C financing and plans to use the proceeds to expand R&D in novel biotechnologies, scale commercial production capabilities, and expand its global strategic presence.